The 12-year retention rate of first-line tumor necrosis factor inhibitors in XXXX : Real-life data from a local registry.

@entity1 @entity1499 @entity309
INTRODUCTION: To evaluate the 12-year survival of the first TNF inhibitor (TNFi) treatment in a cohort of @entity309 ( @entity309 ) @entity1 , comparing the between-groups discontinuation rates for infliximab, etanercept, and adalimumab. METHODS: @entity309 @entity1 treated with their first TNFi were investigated from a local registry. Before and after adjusting for propensity scores, overall and by individual TNFi 12-year drug retention was evaluated. Drug survival rates were calculated using Kaplan-Meier method and compared by Cox extended model. Sub-analyses were performed according to concomitant @entity1499 and discontinuation reasons. RESULTS: 222/583 @entity1 were treated with infliximab, 179 with etanercept, 182 with adalimumab; 33.7% and 26% discontinued the first TNFi because of inefficacy or adverse events, respectively. The overall 12-year drug survival rates for unmatched population were 23.4%. In the propensity score adjusted population, the HR for treatment discontinuation was significantly greater for adalimumab and infliximab versus etanercept (2.89 [95% CI 2.2-3.78] and 2.56 [95% CI 1.92-3.4]), respectively), no difference was found between and for adalimumab versus infliximab (1.16 [95% CI 0.91-1.47]). The incidence of withdrawal due to secondary inefficacy was stable from 3 to 12 years for etanercept, but progressively increased for monoclonal antibodies. Concomitant @entity1499 significantly increased the survival of both adalimumab and etanercept (HR 1.48, 95% CI 1.18-1.86). CONCLUSIONS: The overall 12-year drug survival rate was 23.4%, being significantly higher for etanercept than adalimumab and infliximab. Etanercept discontinuations for inefficacy did not increase from 3 to 12 years. Concomitant @entity1499 increased adalimumab and etanercept drug survival. This article is protected by copyright. All rights reserved.
